Hengrui Pharmaceutical (600276.SH): SHR-4610 injections and other drugs obtained drug clinical trial approval notice

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue the “Drug Clinical Trial Approval Notice” for SHR-4610 injections, SHR-9839 (sc) injections for injections, SHR-4849 injections, SHR-7787 injections, and HRS-4508 tablets.

According to the “Drug Administration Law of the People's Republic of China” and related regulations, after review, the SHR-4610 injection, SHR-9839 (sc) injection, SHR-A2102 for injection, SHR-4849 injection, SHR-7787 injection, and HRS-4508 tablets accepted on August 5, 2026 met the relevant requirements for drug registration and agreed to conduct clinical trials. Specifically, an open, multicenter phase IB/II clinical study on the safety, tolerability, and efficacy of SHR-4610 injection combined with other anti-tumor treatments in advanced solid tumor trial participants.